Stockscreener 앱 받기
6.41
0.47%
0.03
시간 외 거래:
6.31
-0.10
-1.56%
전일 마감가:
$6.38
열려 있는:
$6.38
하루 거래량:
8,361
Relative Volume:
0.36
시가총액:
$23.76M
수익:
$11.68M
순이익/손실:
$-8.85M
주가수익비율:
-2.6598
EPS:
-2.41
순현금흐름:
$-14.61M
1주 성능:
-1.45%
1개월 성능:
+18.70%
6개월 성능:
+211.17%
1년 성능:
+227.04%
1일 변동 폭
$6.2307
$6.41
1주일 범위
$6.2307
$6.80
52주 변동 폭
$1.72
$10.40
Pulmatrix Inc Stock (PULM) Company Profile
명칭
Pulmatrix Inc
전화
(888) 355-4440
주소
945 CONCORD STREET, FRAMINGHAM, MA
PULM을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PULM
Pulmatrix Inc
|
6.41 | 23.76M | 11.68M | -8.85M | -14.61M | -2.41 |
|
VRTX
Vertex Pharmaceuticals Inc
|
500.19 | 127.64B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
603.50 | 65.95B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
656.65 | 37.92B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
273.55 | 32.98B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
254.16 | 26.89B | 3.81B | -644.79M | -669.77M | -6.24 |
Pulmatrix Inc Stock (PULM) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2018-02-09 | 개시 | H.C. Wainwright | Buy |
Pulmatrix Inc 주식(PULM)의 최신 뉴스
Geode Capital Management LLC Boosts Holdings in Pulmatrix, Inc. (NASDAQ:PULM) - Defense World
Pulmatrix, Inc. (NASDAQ:PULM) Holdings Cut by Renaissance Technologies LLC - Defense World
Press Release Distribution & PR Platform - ACCESS Newswire
(PULM) Investment Analysis - news.stocktradersdaily.com
Pulmatrix appoints CBIZ as new auditor after Marcum resignation By Investing.com - Investing.com India
Pulmatrix appoints CBIZ as new auditor after Marcum resignation - Investing.com
Pulmatrix Will Discuss Progress At The Aegis Growth Conference On September 21, 2016 - BioSpace
Aspergillosis Market on Track for Major Expansion by 2034, According to DelveInsight | F2G, Pulmatrix, TFF Pharmaceuticals, Scynexis, Pulmocide - The Globe and Mail
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PULM and ENTO on Behalf of Shareholders - ACCESS Newswire
Pulmatrix : Reports 2018 Financial Results; Provides 2019 Outlook on Pulmonary Disease Pipeline - MarketScreener
Learn to Evaluate (PULM) using the Charts - news.stocktradersdaily.com
Pulmatrix Reports 2024 Financials and Merger Plans - TipRanks
Pulmatrix Announces Divestment Plan for Assets - citybiz
Pulmatrix Inc. (PULM) reports earnings - Quartz
Pulmatrix Announces Year-End and Fourth Quarter 2024 Financial Results and Divestment Plan for Assets - Nasdaq
Pulmatrix (NASDAQ:PULM) Stock Price Crosses Above Fifty Day Moving Average – What’s Next? - Defense World
(PULM) Trading Report - Stock Traders Daily
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates TGI, PULM, CCNE, TURN on Behalf of Shareholders - The Malaysian Reserve
2025-02-25 | SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates TGI, PULM, CCNE, TURN on Behalf of Shareholders | NDAQ:CCNE | Press Release - Stockhouse
SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Pulmatrix, Inc. (PULM) - TradingView
PULM Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Pulmatrix, Inc. Is Fair to Shareholders - Business Wire
PULM stock soars to 52-week high, touches $8.5 amid robust gains - Investing.com India
PULM stock soars to 52-week high, touches $8.5 amid robust gains By Investing.com - Investing.com South Africa
Pulmatrix revises bylaws, changes voting standards - MSN
Pulmatrix revises bylaws, changes voting standards By Investing.com - Investing.com Nigeria
(PULM) Proactive Strategies - Stock Traders Daily
Pulmatrix's Unique Inhaled Drug Candidate Has "Blockbuster" Potential, Says CFO Bill Duke - ACCESS Newswire
Cullgen Begins Phase 1 Dosing of its Potential First-in-Class, Oral Pan-TRK Protein Degrader for Acute and Chronic Pain - The Manila Times
SEC Form 425 filed by Pulmatrix Inc. - Quantisnow
Cullgen Begins Phase 1 Dosing of its Potential - GlobeNewswire
Aspergillosis Market Expected to rise, 2034 | Regeneron, Pulmocide, Astellas Pharma, Cipla, Pulmatrix, F2G, Cellix Bio, SCYNEXIS, TFF, Matinas BioPharma, Amplyx Pharmaceuticals, Cidara Therapeutics, I - The Globe and Mail
Pulmatrix (NASDAQ:PULM) Coverage Initiated by Analysts at StockNews.com - Defense World
Pulmatrix (NASDAQ:PULM) Earns Hold Rating from Analysts at StockNews.com - Defense World
Pulmatrix, Inc. Holds 2024 Annual Meeting of Stockholders – Final Voting Results Released - Defense World
Pulmatrix secures director positions and ratifies accounting firm - Investing.com India
Pulmatrix secures director positions and ratifies accounting firm By Investing.com - Investing.com Australia
StockNews.com Begins Coverage on Pulmatrix (NASDAQ:PULM) - Defense World
Pulmatrix (NASDAQ:PULM) Now Covered by StockNews.com - Defense World
Cullgen Entering Public Market with Pulmatrix Merger - San Diego Business Journal
Pulmatrix Announces Third Quarter 2024 Financial Results and Pro - GuruFocus.com
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CDE, ALVR, PULM, ENTO on Behalf of Shareholders - The Malaysian Reserve
Finansavisen - Finansavisen
Pulmatrix and Cullgen announce proposed merger - MSN
Stock Market News: Samfine Creation Holdings drops by 21.56% while Pulmatrix dropped by almost 15% during mid day trading - Business Upturn
Pulmatrix, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Pulmatrix (NASDAQ:PULM) Coverage Initiated at StockNews.com - Defense World
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates - GlobeNewswire
PULMATRIX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Pulmatrix, Inc.PULM - Marketscreener.com
Pulmatrix Inc (PULM) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.39%
0.52%
자본화:
|
볼륨(24시간):